Estados financieros detallados de Century Therapeutics, Inc. (IPSC): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.86, IPSC presenta beneficios negativos (P/E no significativo) y un ROE del -52.76%. La capitalización bursátil es de $161M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | $5.2M | $2.2M | $6.6M | $109.2M |
| Coste de Ventas | $249000 | $1.8M | $4.6M | 0 | 0 | 0 | $13.1M |
| Beneficio Bruto | -$249000 | -$1.8M | -$4.6M | $5.2M | $2.2M | $6.6M | $96.1M |
| I+D | $14.3M | $39.7M | $75.6M | $97.2M | $92.7M | $107.2M | $95.7M |
| Generales y Administrativos | $5.5M | $7.7M | $14.7M | $31.9M | $34.7M | $33.2M | $24.0M |
| Gastos Operativos | $19.8M | $47.4M | $90.3M | $139.0M | $148.8M | $144.7M | $111.1M |
| Beneficio Operativo | -$20.0M | -$49.2M | -$94.9M | -$133.8M | -$146.5M | -$138.1M | -$15.0M |
| EBITDA | -$244.5M | -$51.4M | -$89.9M | -$121.2M | -$121.2M | -$111.5M | $3.5M |
| Gastos por Intereses | 0 | $381000 | $1.3M | 0 | $540000 | 0 | 0 |
| Beneficio Antes de Impuestos | -$244.8M | -$53.6M | -$95.8M | -$130.8M | -$134.8M | -$124.8M | -$9.6M |
| Impuestos | 0 | 0 | $43000 | $91000 | $1.9M | $1.8M | -$68000 |
| Beneficio Neto | -$244.8M | -$53.6M | -$95.8M | -$130.9M | -$136.7M | -$126.6M | -$9.6M |
| BPA | $-4.49 | $-1.00 | $-1.74 | $-2.27 | $-2.30 | $-1.61 | $-0.11 |
| BPA Diluido | $-4.49 | $-1.00 | $-1.74 | $-2.27 | $-2.30 | $-1.61 | $-0.11 |
| Acciones en Circulación (Diluidas) | $54.8M | $54.8M | $55.0M | $57.8M | $59.3M | $78.6M | $86.6M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$22.5M | 0 | -$3.0M | 0 |
| Beneficio Operativo | -$36.1M | -$20.7M | -$25.5M | -$36.5M |
| EBITDA | -$26.2M | -$15.7M | -$18.6M | -$34.5M |
| Beneficio Neto | -$34.4M | -$19.2M | -$21.6M | -$34.5M |
| BPA | $-0.40 | $-0.22 | $-0.25 | $-0.17 |
| BPA Diluido | $-0.40 | $-0.22 | $-0.25 | $-0.17 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $44.1M | $27.2M | $56.4M | $84.3M | $47.3M | $58.4M | $61.9M |
| Inversiones a Corto | $37.5M | $48.5M | $166.4M | $231.2M | $125.4M | $130.9M | $55.3M |
| Cuentas por Cobrar | $123000 | $908000 | $250000 | $780000 | $665000 | $1.5M | $667000 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $84.1M | $78.8M | $228.2M | $319.7M | $177.0M | $194.1M | $120.8M |
| Inmovilizado Material | $2.5M | $24.8M | $69.8M | $111.7M | $92.1M | $90.8M | $66.2M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | $9.4M | 0 | 0 | 0 | $34.2M | $34.2M |
| Activos Totales | $90.9M | $106.8M | $437.4M | $486.5M | $360.7M | $353.2M | $223.7M |
| Cuentas por Pagar | $1.5M | $8.1M | $7.6M | $5.5M | $2.7M | $3.1M | $4.8M |
| Deuda a Corto | 0 | 0 | $1.0M | $6.5M | $1.5M | 0 | 0 |
| Pasivos Corrientes | $3.0M | $12.1M | $15.7M | $29.8M | $17.8M | $129.8M | $20.2M |
| Deuda a Largo | 0 | $9.6M | $8.9M | $3.7M | 0 | 0 | 0 |
| Pasivos Totales | $182.8M | $213.2M | $41.1M | $183.8M | $175.9M | $191.9M | $64.8M |
| Reservas | -$238.8M | -$292.3M | -$388.2M | -$519.1M | -$655.8M | -$782.3M | -$791.9M |
| Patrimonio Neto | -$91.9M | -$106.4M | $396.2M | $302.7M | $184.8M | $161.4M | $158.9M |
| Deuda Total | 0 | $21.6M | $25.1M | $49.4M | $48.2M | $53.8M | $43.6M |
| Deuda Neta | -$81.5M | -$54.2M | -$197.8M | -$266.1M | -$124.6M | -$135.5M | -$73.5M |
| Capital Circulante | $81.1M | $66.7M | $212.5M | $289.9M | $159.1M | $64.3M | $100.5M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $55.5M | $61.9M | $51.0M | $49.6M |
| Activos Totales | $244.7M | $223.7M | $326.6M | $287.0M |
| Pasivos Totales | $68.4M | $64.8M | $61.8M | $54.7M |
| Patrimonio Neto | $176.3M | $158.9M | $264.7M | $232.3M |
| Deuda Total | $45.0M | $43.6M | $48.0M | $34.6M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$244.8M | -$53.6M | -$95.8M | -$130.9M | -$136.7M | -$126.6M | -$9.6M |
| Amortizaciones | $249000 | $1.4M | $3.7M | $8.4M | $13.0M | $13.3M | $13.1M |
| Compensación en Acciones | $147000 | $876000 | $4.7M | $10.7M | $14.6M | $12.7M | $6.8M |
| Cambio en Capital Circulante | $2.3M | $4.9M | -$2.8M | $123.9M | $9.4M | -$9.3M | -$114.6M |
| Flujo de Caja Operativo | -$16.2M | -$41.3M | -$89.0M | $14.1M | -$88.3M | -$110.1M | -$103.9M |
| Inversiones (CapEx) | -$2.5M | -$9.8M | -$45.0M | -$30.6M | -$13.7M | -$154000 | -$848000 |
| Adquisiciones | 0 | 0 | 0 | -$238.2M | 0 | -$9.6M | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$18.6M | -$51.1M | -$134.0M | -$16.6M | -$102.1M | -$110.3M | -$104.7M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$25.6M | -$16.1M | -$25.2M | -$19.8M |
| Inversiones (CapEx) | -$195000 | -$317000 | -$584000 | -$694000 |
| Flujo de Caja Libre | -$25.8M | -$16.4M | -$25.8M | -$20.5M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $892000 | $1.3M | $1.4M | $1.9M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | | | -57.0% | +194.8% | +1556.8% |
| Crecimiento Beneficio Neto (anual) | | +78.1% | -78.9% | -36.6% | -4.4% | +7.4% | +92.4% |
| Crecimiento BPA (anual) | | +77.7% | -74.0% | -30.5% | -1.3% | +30.0% | +93.2% |
| Cambio en Acciones (anual) | | +0.0% | +0.3% | +5.0% | +2.7% | +32.6% | +10.1% |
| Crecimiento FCF (anual) | | -174.3% | -162.2% | +87.6% | -516.7% | -8.0% | +5.0% |
| Margen Bruto | | | | 100.0% | 100.0% | 100.0% | 88.0% |
| Margen Operativo | | | | -2574.2% | -6556.9% | -2096.5% | -13.8% |
| Margen EBITDA | | | | -2331.2% | -5423.2% | -1691.8% | 3.2% |
| Margen Neto | | | | -2518.4% | -6115.1% | -1920.9% | -8.8% |
| Margen FCF | | | | -318.4% | -4567.5% | -1673.8% | -95.9% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.1% | -1.4% | -1.4% | 0.7% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.34 | $-0.93 | $-2.44 | $-0.29 | $-1.72 | $-1.40 | $-1.21 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $54.8M | $54.8M | $55.0M | $57.8M | $59.3M | $78.6M | $86.6M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -52.76% |
| Rentabilidad sobre capital invertido | -43.66% |
| Rentabilidad sobre activos | -38.25% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.15 |
| Ratio corriente | 8.28 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -5.08 | -22.83 | -9.11 | -2.26 | -1.44 | -0.63 | -9.04 |
| P/VC | -13.63 | -11.76 | 2.20 | 0.98 | 1.07 | 0.49 | 0.54 |
| P/V | 0.00 | 0.00 | 0.00 | 56.99 | 88.11 | 12.06 | 0.79 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | 88.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | -2574.2% | -6556.9% | -2096.5% | -13.8% |
| Margen Neto | 0.0% | 0.0% | 0.0% | -2518.4% | -6115.1% | -1920.9% | -8.8% |